Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-d-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380 · cited 1×
“In the prototypical antioxidant trial, vitamin E (1000 IU twice a day) and selegiline (5 mg twice a day), each given alone to moderately impaired patients with AD, delayed the time until patients required nursing home placement, died, or lost ADL (Sano et al. 1997).”
BackgroundSelf-citationShumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
Petersen, R. C., Thomas, R. G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050151 · Cited by 1,844 · cited 1×
“A multicenter trial in MCI patients reported no significant delay in conversion to AD or dementia in cognitive effects with a-tocopherol (or donepezil) over 3 years of treatment (Petersen et al. 2005).”
BackgroundTariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Craft, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.233 · Cited by 1,253
McKeith, I., Del Ser, T., Spano, P., Emre, M., Wesnes, K., Anand, R., Cicin-Sain, A., Ferrara, R., & Spiegel, R. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03399-7 · Cited by 1,182
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
Tuszynski, M. H., Thal, L., Pay, M., Salmon, D. P., U, H. S., Bakay, R., Patel, P., Blesch, A., Vahlsing, H. L., Ho, G., et al. (2005) · Nature Medicine · doi:10.1038/nm1239 · Cited by 1,050 · cited 1×
“A Phase I study of stereotactic NGF gene delivery using transformed fibroblasts derived from skin biopsies showed that NGF expression could be induced in nucleus basalis cells in humans with AD, with some evidence of increased brain function by FDG-PET scanning (Tuszynski et al. 2005).”
BackgroundSchneider, L. S., Dagerman, K., & Insel, P. S. (2006) · The American Journal of Geriatric Psychiatry · doi:10.1097/01.jgp.0000200589.01396.6d · Cited by 903
Self-citation(2004) · The Lancet · doi:10.1016/s0140-6736(04)16499-4 · Cited by 892
Smith, A. D., Smith, S. M., de Jager, C. A., Whitbread, P., Johnston, C., Agacinski, G., Oulhaj, A., Bradley, K. M., Jacoby, R., & Refsum, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012244 · Cited by 813 · cited 1×
“A study of a similar regimen in individuals with MCI showed reduction of whole brain atrophy with vitamin use for 2 years (Smith et al. 2010).”
ResultDocosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764 · cited 1×
“An NIA-funded trial of DHA for mild to moderate AD was, however, negative (Quinn et al. 2010).”
BackgroundSelf-citationErkinjuntti, T., Kurz, A., Gauthier, S., Bullock, R., Lilienfeld, S., & Damaraju, C. V. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08267-3 · Cited by 752
Risner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
Ballard, C., Hanney, M. L., Theodoulou, M., Douglas, S., McShane, R., Kossakowski, K., Gill, R., Juszczak, E., Yu, L.-M., & Jacoby, R. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70295-3 · Cited by 567
Kavirajan, H., & Schneider, L. S. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70195-3 · Cited by 497
Self-citationStatins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub3 · Cited by 490
Craft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487 · cited 1×
“There is evidence that diabetes may increase the risk of AD, and a variety of animal and human studies support the concept that insulin resistance in brain may play a role in AD (Craft 2007).”
BackgroundA randomized controlled trial of prednisone in Alzheimer’s disease
Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., Weiner, M. F., Farlow, M. R., Sano, M., Grundman, M., et al. (2000) · Neurology · doi:10.1212/wnl.54.3.588 · Cited by 464
Self-citationEfficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia
Tariot, P. N., Erb, R., Podgorski, C. A., Cox, C., Patel, S., Jakimovich, L., & Irvine, C. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.54 · Cited by 422 · cited 1×
“Early trials suggested the benefit of carbamazepine as a treatment for agitation (Tariot et al. 1998).”
BackgroundEfficacy of PPAR-γ agonist pioglitazone in mild Alzheimer disease
Sato, T., Hanyu, H., Hirao, K., Kanetaka, H., Sakurai, H., & Iwamoto, T. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.009 · Cited by 387
Black, S., Román, G. C., Geldmacher, D. S., Salloway, S., Hecker, J., Burns, A., Perdomo, C., Kumar, D., & Pratt, R. (2003) · Stroke · doi:10.1161/01.str.0000091396.95360.e1 · Cited by 386 · cited 2×
“AChE-Is have also been assessed in clinical trials of vascular dementia (Black et al. 2003; Kavirajan and Schneider 2007), mixed AD and cerebrovascular disease (Erkinjuntti et al. 2002), and dementia with Lewy bodies (McKeith et al. 2000).”
MethodGold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361 · cited 1×
“demonstrate significant benefit (Harrington et al. 2009; Gold et al. 2010), although post-hoc analysis in an early study suggested benefit in the APOE 14 negative subgroup (Risner et al.”
BackgroundNaproxen and celecoxib do not prevent AD in early results from a randomized controlled trial
ADAPT Research Group (2007) · Neurology · doi:10.1212/01.wnl.0000260269.93245.d2 · Cited by 354 · cited 1×
“2000), nonsteroidal anti-inflammatory drugs (both nonselective and COX-2 selective) (Aisen et al. 2003; Lyketsos et al. 2007), hydroxychloroquine (Van Gool et al.”
BackgroundPravastatin and cognitive function in the elderly. Results of the PROSPER study
Trompet, S., Vliet, P., Craen, A. J. M., Jolles, J., Buckley, B. M., Murphy, M. B., Ford, I., Macfarlane, P. W., Sattar, N., Packard, C. J., et al. (2010) · Journal of Neurology · doi:10.1007/s00415-009-5271-7 · Cited by 291 · cited 1×
“A randomized, placebo-controlled trial of pravastatin in 5804 subjects with risk factors for vascular disease reported favorable cardiovascular outcomes but no significant effect on cognitive function or disability during an approximately 3-year follow-up period (Trompet et al. 2010).”
BackgroundPorsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272 · cited 2×
“2006); two trials did not show significant drug–placebo differences (Bakchine and Loft 2008; Porsteinsson et al. 2008).”
BackgroundLopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266 · cited 4×
“Although some long-term open-label observations suggest that combination therapy with an ACHE-I and memantine may ameliorate the course of AD (Lopez et al. 2009; Rountree et al. 2009), other studies suggest otherwise (Schneider et al. 2011).”
BackgroundInfluentialKales, H. C., Valenstein, M., Kim, H. M., McCarthy, J. F., Ganoczy, D., Cunningham, F., & Blow, F. C. (2007) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06101710 · Cited by 258 · cited 1×
“Long-term observations suggest that continuing therapy is associated with a continuing increased risk for mortality (Kales et al. 2007; Ballard et al. 2009).”
BackgroundSertraline for the treatment of depression in Alzheimer disease
Rosenberg, P. B., Martin, B. K., Frangakis, C., Mintzer, J. E., Weintraub, D., Porsteinsson, A. P., Schneider, L. S., Rabins, P. V., Munro, C. A., Meinert, C. L., et al. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181c796eb · Cited by 250 · cited 1×
“Clinical trials have been largely negative in showing benefit for treatment of depression in AD with antidepressant medications (Lyketsos et al. 2000; Olin et al. 2002; Rosenberg et al. 2010; Weintraub et al. 2010).”
BackgroundSelf-citationGeldmacher, D. S., Fritsch, T., McClendon, M. J., & Landreth, G. (2011) · Archives of Neurology · doi:10.1001/archneurol.2010.229 · Cited by 221 · cited 1×
“However, a study of a pioglitazone found mixed results, with no difference on most cognitive measures (Sato et al. 2009; Geldmacher et al. 2011).”
ResultStatins for the prevention of dementia
McGuinness, B., Craig, D., Bullock, R., & Passmore, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003160.pub2 · Cited by 193 · cited 1×
“Two large placebo-controlled trials, one with simvastatin and another with atorvastatin, over 18 months did not show positive effects for the drugs in slowing the clinical decline (McGuinness et al. 2009).”
BackgroundRountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181 · cited 4×
“Although some long-term open-label observations suggest that combination therapy with an ACHE-I and memantine may ameliorate the course of AD (Lopez et al. 2009; Rountree et al. 2009), other studies suggest otherwise (Schneider et al. 2011).”
BackgroundInfluentialAisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Self-citation
Cited by
Epidemiology of Alzheimer Disease
Mayeux, R., & Stern, Y. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006239 · Cited by 1,064
Rabinovici, G. D., Gatsonis, C., Apgar, C., Chaudhary, K., Gareen, I., Hanna, L., Hendrix, J., Hillner, B. E., Olson, C., Lesman-Segev, O. H., et al. (2019) · JAMA · doi:10.1001/jama.2019.2000 · Cited by 674
Vellas, B., Coley, N., Ousset, P.-J., Berrut, G., Dartigues, J.-F., Dubois, B., Grandjean, H., Pasquier, F., Piette, F., Robert, P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70206-5 · Cited by 398
Rabinovici, G. D. (2019) · Continuum · doi:10.1212/con.0000000000000700 · Cited by 170
Physical exercise neuroprotects ovariectomized 3xTg-AD mice through BDNF mechanisms
García-Mesa, Y., Pareja-Galeano, H., Bonet-Costa, V., Revilla, S., Gómez-Cabrera, M. C., Gambini, J., Giménez-Llort, L., Cristòfol, R., Viña, J., & Sanfeliu, C. (2014) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2014.03.021 · Cited by 68
“support of such cognitive benefits for AD patients (Kamat et al., 2008; Aisen et al., 2012).”
Background
Metadata
- Authors
- Aisen, P. S., Cummings, J., & Schneider, L. S.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-11-30
- Volume
- 2
- Issue
- 3
- Pages
- a006395-a006395
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2142564978
- Cited by
- 81
- References
- 35
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.